JP2013510122A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510122A5
JP2013510122A5 JP2012537380A JP2012537380A JP2013510122A5 JP 2013510122 A5 JP2013510122 A5 JP 2013510122A5 JP 2012537380 A JP2012537380 A JP 2012537380A JP 2012537380 A JP2012537380 A JP 2012537380A JP 2013510122 A5 JP2013510122 A5 JP 2013510122A5
Authority
JP
Japan
Prior art keywords
phenyl
methyl
alkyl
triazolo
benzodiazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012537380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510122A (ja
Filing date
Publication date
Priority claimed from GBGB0919426.7A external-priority patent/GB0919426D0/en
Application filed filed Critical
Publication of JP2013510122A publication Critical patent/JP2013510122A/ja
Publication of JP2013510122A5 publication Critical patent/JP2013510122A5/ja
Withdrawn legal-status Critical Current

Links

JP2012537380A 2009-11-05 2010-11-03 ブロモドメイン阻害剤としての縮合アゼピン誘導体 Withdrawn JP2013510122A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0919426.7A GB0919426D0 (en) 2009-11-05 2009-11-05 Novel compounds
GB0919426.7 2009-11-05
PCT/EP2010/066696 WO2011054844A1 (en) 2009-11-05 2010-11-03 Condensed azepine derivatives as bromodomain inhibitors

Publications (2)

Publication Number Publication Date
JP2013510122A JP2013510122A (ja) 2013-03-21
JP2013510122A5 true JP2013510122A5 (enExample) 2013-11-28

Family

ID=41501969

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012537380A Withdrawn JP2013510122A (ja) 2009-11-05 2010-11-03 ブロモドメイン阻害剤としての縮合アゼピン誘導体

Country Status (5)

Country Link
US (1) US20120202799A1 (enExample)
EP (1) EP2496581A1 (enExample)
JP (1) JP2013510122A (enExample)
GB (1) GB0919426D0 (enExample)
WO (1) WO2011054844A1 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
MX384074B (es) 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033270A2 (en) * 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
WO2013033269A1 (en) * 2011-08-29 2013-03-07 Coferon, Inc. Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP2838881B1 (en) 2012-04-20 2018-08-08 AbbVie Inc. Isoindolone derivatives
TWI602820B (zh) * 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
WO2013185284A1 (en) 2012-06-12 2013-12-19 Abbott Laboratories Pyridinone and pyridazinone derivatives
EP2861255B1 (en) 2012-06-19 2019-10-09 The Broad Institute, Inc. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
PE20150729A1 (es) 2012-08-16 2015-06-14 Bayer Pharma AG 2,3-benzodiazepines
HK1208448A1 (en) 2012-09-28 2016-03-04 Bayer Pharma Aktiengesellschaft Bet protein-inhibiting 5-aryl triazole azepines
JP6401773B2 (ja) 2013-03-11 2018-10-10 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Betブロモドメイン阻害剤およびこれを用いる治療方法
CN105026403B (zh) * 2013-03-12 2018-05-18 艾伯维公司 四环布罗莫结构域抑制剂
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
WO2014159837A1 (en) * 2013-03-14 2014-10-02 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
US9227985B2 (en) 2013-03-15 2016-01-05 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
WO2014173241A1 (en) 2013-04-26 2014-10-30 Beigene, Ltd. Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
WO2015013635A2 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
EP3066101B1 (en) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
JP2017504650A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド ジアゼパン誘導体およびその使用
KR20160130778A (ko) * 2014-02-28 2016-11-14 텐샤 세러퓨틱스 인코포레이티드 고인슐린혈증과 관련된 질환의 치료
JP2017511801A (ja) 2014-02-28 2017-04-27 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン BETブロモドメイン阻害剤としての9H−ピリミド[4,5−b]インドールおよび関連類似体
CN106132968B (zh) * 2014-04-09 2019-04-05 康佳诺医疗科技发展有限公司 一种用于防止或治疗癌症的抑制溴结构域的化合物及含有该化合物的药物组合物
MY180775A (en) 2014-04-23 2020-12-09 Incyte Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
PL3157928T3 (pl) 2014-06-20 2019-07-31 Constellation Pharmaceuticals, Inc. Krystaliczne postacie 2-((4S)-6-(4-chlorofenylo)-1-metylo-4H-benzo[ c]izoksazolo-[4,5-e]azepin-4-ylo)acetamidu
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
MX2017001757A (es) 2014-08-08 2017-05-30 Dana Farber Cancer Inst Inc Derivados de dihidropteridinona y sus usos.
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US10307407B2 (en) 2015-02-27 2019-06-04 The Regents Of The University Of Michigan 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016196065A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Methods and compositions for assessing responsiveness of cancers to bet inhibitors
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
BR112017028178A2 (en) 2015-06-26 2018-08-28 Tensha Therapeutics, Inc. nut midline carcinoma treatment
KR20180035905A (ko) 2015-08-10 2018-04-06 다나-파버 캔서 인스티튜트 인크. Bet 브로모도메인 억제제에 대한 저항성의 메카니즘
WO2017037567A1 (en) * 2015-09-03 2017-03-09 Pfizer Inc. Regulators of frataxin
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
UA123946C2 (uk) 2015-09-11 2021-06-30 Дана-Фарбер Кенсер Інстітьют, Інк. Ацетамідтієнотриазолодіазепіни й шляхи їх застосування
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CA3003288A1 (en) 2015-11-25 2017-06-01 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
AU2016363632A1 (en) 2015-12-03 2018-06-07 Bayer Cropscience Aktiengesellschaft Mesoionic halogenated 3-(acetyl)-1-((1,3-thiazol-5-yl)methyl)-1h-imidazo(1,2-a)pyridin-4-ium-2-olate derivatives and related compounds as insecticides
JP6967522B2 (ja) 2016-02-15 2021-11-17 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Betブロモドメイン阻害剤としての融合1,4−オキサゼピンおよび関連類似体
JP7037500B2 (ja) 2016-04-06 2022-03-16 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Mdm2タンパク質分解剤
AU2017246453A1 (en) 2016-04-06 2018-11-08 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
AU2017250076B2 (en) 2016-04-12 2021-07-22 The Regents Of The University Of Michigan Bet protein degraders
ES2793239T3 (es) 2016-04-15 2020-11-13 Abbvie Inc Inhibidores del bromodominio
KR102643344B1 (ko) 2016-06-20 2024-03-07 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
WO2018022802A1 (en) 2016-07-26 2018-02-01 University Of Southern California Selective bromodomain inhibition of fungal bdf1
CN110062759B (zh) 2016-09-13 2022-05-24 密执安大学评议会 作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬
ES2857743T3 (es) 2016-09-13 2021-09-29 Univ Michigan Regents 1,4-diazepinas fusionadas como degradadores de proteína BET
US11046709B2 (en) 2017-02-03 2021-06-29 The Regents Of The University Of Michigan Fused 1,4-diazepines as BET bromodomain inhibitors
CN108727380A (zh) * 2017-04-13 2018-11-02 中国科学院上海药物研究所 一种brd4抑制剂及其制备和应用
BR112019025331A2 (pt) 2017-06-16 2020-06-23 Basf Se Compostos da fórmula (i), composição, métodos de proteção de safras e de combate, método não terapêutico de tratamento, semente, uso dos compostos e uso de composto
US11267822B2 (en) 2017-09-13 2022-03-08 The Regents Of The University Of Michigan BET bromodomain protein degraders with cleavable linkers
JP7402857B2 (ja) 2018-04-04 2023-12-21 エピオダイン,インク. オピオイド受容体モジュレーター、およびそれに関連する生成物ならびに方法
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
AR122707A1 (es) 2020-06-23 2022-09-28 Genentech Inc Compuestos macrocíclicos y métodos de uso de los mismos
TW202304869A (zh) 2021-04-05 2023-02-01 美商艾碧奧戴股份有限公司 類鴉片受體調節劑
WO2023041744A1 (en) 2021-09-17 2023-03-23 Institut Curie Bet inhibitors for treating pab1 deficient cancer
JP2025514712A (ja) 2022-04-19 2025-05-09 ヌエヴォリューション・アクティーゼルスカブ ブロモドメインに対して活性な化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
WO1993007129A1 (fr) * 1991-10-11 1993-04-15 Yoshitomi Pharmaceutical Industries, Ltd. Medicament utilise pour traiter l'osteoporose et compose de diazepine
JPH06128257A (ja) * 1992-10-13 1994-05-10 Yoshitomi Pharmaceut Ind Ltd ピリドジアゼピン化合物
JP2840454B2 (ja) * 1993-11-22 1998-12-24 メルク エンド カンパニー インコーポレーテッド ベンゾジアゼピン類
IL127516A0 (en) * 1996-06-12 1999-10-28 Japan Tobacco Inc A cytokine production inhibitor
CN1901958B (zh) 2003-11-03 2011-03-09 葛兰素集团有限公司 流体分配装置
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Brd2ブロモドメイン結合剤
US8476260B2 (en) 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent

Similar Documents

Publication Publication Date Title
HRP20170638T1 (hr) MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI
JP2016523923A5 (enExample)
JP2014502979A5 (enExample)
JP2013510123A5 (enExample)
JP2017523972A5 (enExample)
JP2016501250A5 (enExample)
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
JP2011529037A5 (enExample)
JP2014511891A5 (enExample)
JP2012508252A5 (enExample)
RU2014113679A (ru) N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1
JP2013543896A5 (enExample)
JP2005535586A5 (enExample)
JP2010500345A5 (enExample)
SI2824100T1 (en) 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase
JP2015522607A5 (enExample)
RU2019136279A (ru) C5 -Анилинохиназолиновые соединения и их использование в лечении рака
JP2007520440A5 (enExample)
RU2014101464A (ru) Циклопропил-конденсированные-1,3-тиазепины в качестве ингибиторов васе 1 и(или) васе 2
JP2010536821A5 (enExample)
JP2020521772A5 (enExample)
RU2014121394A (ru) Двузамещенные соединения диамино-3,4-циклобутен-3-диона-1,2, приемлемые для лечения паталогий, опосредованных хемокинами
JP2015526453A5 (enExample)
JP2018048143A5 (enExample)
JP2013506003A5 (enExample)